ArticleDiscover oncology2025
Metabolomic Understanding of variable risk factors for kidney cancer: a two-sample Mendelian randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundCirculating metabolites have been found to play an important role in the development of renal cancer, however, the specific pathways and mechanisms of their influence are still largely unknown. We aimed to investigate the role of metabolites in kidney cancer development and to explain the development of kidney cancer from a genetic perspective.
methodWe explored the role of plasma metabolites and urinary metabolites in kidney cancer using two-sample mendelian randomization (MR) separately and validated it using multiple databases; in addition, we performed rigorous tests of pleiotropy and heterogeneity to ensure that the results were robust. Next, we explored the role of common modifiable risk factors in kidney cancer and identified the specific mechanisms by which risk factors affect kidney cancer by joint analysis of TCGA and GEO databases.
resultsThrough MR analysis, we identified six plasma metabolites and one urinary metabolite that play a major role in kidney cancer, confirmed the effects of BMI and type 1 diabetes mellitus on kidney cancer, and constructed the BMI-plasma metabolite-kidney cancer causality networks through mediated MR. In addition, we found that SLPI could significantly affect the prognosis of kidney cancer through multiple databases' joint analyses, and through multiple methods explored the pathways of SLPI's influence on kidney cancer.
conclusionsIn a word, this study shows that BMI can significantly increase the risk of kidney cancer, while the plasma metabolites 4-guanidinobutanoate may partially mitigate this risk, and that SLPI promotes tumorigenesis in obesity-related renal cancer by regulating protease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.